<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602651</url>
  </required_header>
  <id_info>
    <org_study_id>N°ID-RCB : 2018-A01516-49</org_study_id>
    <nct_id>NCT03602651</nct_id>
  </id_info>
  <brief_title>MAGZEN® Effect on Recent Anxiety Reaction</brief_title>
  <acronym>STRESS2</acronym>
  <official_title>MAGZEN® Effect on Recent Anxiety Reaction (STRESS2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire Dielen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire Dielen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentres, observational study, prospective, to evaluate the effect of MAGZEN® in the
      treatment of recent anxiety reaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      107 patients suffering from recent anxiety reaction will be included in the study. They will
      be treated by MAGZEN® during 4 weeks and we will study the effect of this treatment on the
      evolution of their anxiety after the cure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Weeks</target_duration>
  <primary_outcome>
    <measure>number of &quot;responders patients&quot;</measure>
    <time_frame>4 weeks</time_frame>
    <description>number (%) of &quot;responders patients&quot; with a diminution of the HAM-A score ≥ 50 %</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>MAGZEN®</arm_group_label>
    <description>All patient will be treated with MAGZEN® and will be evaluated with the Hamilton-anxiety scale (HAM-A)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hamilton-anxiety scale (HAM-A)</intervention_name>
    <description>Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)</description>
    <arm_group_label>MAGZEN®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients suffuring from a recent anxiety reaction not already treated.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient suffering from recent anxiety reaction

          -  Hamilton-anxiety score ≥ 20 at inclusion

          -  recent anxiety disorders (less than 3 months) not treated by pharmacological or
             psychological treatment

        Exclusion Criteria:

          -  major depressive syndrome

          -  anxiety disorders more than 3 months

          -  anxiety due to death
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric MD ROUILLON</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital St Anne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine NOEL</last_name>
    <phone>+33 2 33 23 43 90</phone>
    <email>contact@dielen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé NACASS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

